While HFpEF risk factors can independently contribute to HF and MF, the interplay of multiple comorbidities and their impact on fibrosis progression and treatment efficacy remain poorly understood (Mall et al., 1990
With FDA approval, insurance compatibility, and a seamless process to aid you every step of the way, Klinic provides the expertise and support you need to pursue effective, sustainable weight loss
In placebo-controlled adjunctive epilepsy trials in adults receiving topiramate 200 to 1,000 mg/day, hot flashes (1% to 2%), drug-induced body odor (0% to 1%), skin disorder (1% to 2%), hyperhidrosis (1% or less), and erythematous rash (1% or less) were reported with equal or greater frequency than placebo
Eating disorder safety: GLP-1 medications affect appetite and food intake
Plus, tirzepatide results in weight loss, including both fat mass and lean body mass